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Toad glandular secretions and skin extractions contain many natural agents which may provide a unique resource for novel drug
development. The dried secretion from the auricular and skin glands of Chinese toad (Bufo bufo gargarizans) is named Chansu,
which has been used in Traditional Chinese Medicine (TCM) for treating infection and inflammation for hundreds of years. The
sterilized hot water extraction of dried toad skin is named Huachansu (Cinobufacini) which was developed for treating hepatitis B
virus (HBV) and several types of cancers. However, the mechanisms of action of Chansu, Huachansu, and their constituents within
are not well reported. Existing studies have suggested that their anti-inflammation and anticancer potential were via targeting
Nuclear Factor (NF)-𝜅B and its signalling pathwayswhich are crucial hallmarks of inflammation and cancer in various experimental
models. Here, we review some current studies of Chansu, Huachansu, and their compounds in terms of their use as both anti-
inflammatory and anticancer agents.We also explored the potential use of toad glandular secretions and skin extractions as alternate
resources for treating human cancers in combinational therapies.
1. Introduction
The link between inflammation and cancer was first sug-
gested by Rudolf Virchow in 1863 [1], but this theory was
largely ignored until recent decades [2]. Statistics have shown
that up to 25% of cancer mortality worldwide is related to
chronic inflammation [3]. Some pieces of the epidemiological
evidence are detailed below.
(a) Infection with Helicobacter pylori is associated with
gastric cancer and gastric mucosal lymphoma [4].
(b) Hepatitis B virus (HBV) and hepatitis C virus (HCV)
related chronic infections contribute to increased risk
of hepatocellular carcinoma (HCC) [5].
(c) Autoimmune diseases such as inflammatory bowel
diseases (IBDs) may trigger colon cancer [6]. Simi-
larly, prostatitis is associated with prostate cancer [7]
and tobacco is also a promoter for lung carcinogenesis
[8].
(d) Long-term use of nonsteroidal anti-inflammatory
drugs (NSAIDs) reduces the risk of several cancers
[9].
Recent studies have revealed the crosstalk between chronic
inflammation and cancer [1, 10]. The microenvironment of
tumours are typically rich in proinflammatory mediators,
such as Tumour Necrosis Factor (TNF)-𝛼, Interleukin (IL)-
1, IL-6, IL-8, cyclooxygenases-2 (COX-2), and inducible
nitrogen synthesis (iNOS) which are essential components
of the tumour initiation and promotion [11, 12]. It has also
been recognised that the transcription factor NF-𝜅B plays a
central coordinator role between inflammation and cancer by
regulating the above mentioned proinflammatory cytokines
and enzymes [13]. Constitutive activation ofNF-𝜅B signalling
has been found in several types of tumours including breast,
colon, prostate, skin, and lymphoid and mediates resistance
to chemo- and radiotherapy [14]. Hence, therapeutic block-
ade ofNF-𝜅B signalling has become a promising target for the
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prevention and treatment of cancer [15]. In another words, an
agent that suppresses NF-𝜅B activation may have potential in
the development of novel anticancer drugs [16].
Natural products have been used extensively in the
treatment of many diseases [17]. Anti-inflammation and
anticancer drugs developed from natural resources have
drawn significant attention throughout the world [18]. The
biodiversity of chemical compounds in the auricular and skin
glands of toads makes them unique sources from which new
therapeutic agents may be developed [19]. Additionally, toad
glandular secretions have been used for treating infection and
inflammation for centuries in Traditional Chinese Medicine
(TCM) in China and East/Southern East Asian countries.
Recent studies have indicated that toad glandular secretions
and skin extractions can be both anti-inflammatory and
anticancer agents. Therefore, this type of natural products
may provide a potential new strategy as combinational and/or
complimentary therapies for cancer treatment by targeting
key NF-𝜅B signalling molecules and their pathways.
2. Inflammation and Cancer
Inflammation is part of a mechanism of innate immunity,
providing protection from infection, injury, or irritation [20].
The common inflammatory symptoms include redness, heat,
swelling, pain, and sometimes loss of function in the inflamed
tissue [21]. Inflammation helps heal wounds by clearing the
injurious agents and removing damaged tissue components
[22]. However, if inflammation is not under control promptly,
the inflammatory triggering factors continue stimulating the
tissue; this could result in chronic inflammation, leading to
a wide variety of diseases such as rheumatoid arthritis, heart
attack, Alzheimer’s disease, and cancer [23].
Cancer-related inflammation can be summarized into
two categories. On one hand, chronic inflammatory condi-
tions cause tissue damage which augment the risk of cancer
development [24]. On the other hand, inflammation is also
found in cancer tissues that arose without precancerous
inflammation [25]. Genetic alterations which include muta-
tions, activation of oncogenes, chromosomal rearrangement
or amplification, and the inactivation of tumour-suppressor
genes in tumour cells can induce an inflammatory microen-
vironment [26]. Regardless of the origin of the inflammatory
condition, inflammatory microenvironment is essential for
the maintenance and promotion of cancer progression [27].
3. NF-𝜅B and Its Regulated Gene Products in
Inflammation and Cancer
In cancer-related inflammation, the expression of major
proinflammatory gene products is regulated by NF-𝜅B which
is an important transcription factor that is involved in many
physiological processes including proliferation, apoptosis,
tumourigenesis, inflammation, and various diseases includ-
ing cancer [28]. There are five proteins of two classes in
the mammalian NF-𝜅B family (Class 1: NF-𝜅B1/p50, NF-
𝜅B2/p52; Class 2: RelA/p60, RelB, c-REL). In resting stage,















Figure 1: The activation process of NF-𝜅B.
Inhibitor 𝜅B (I𝜅B) to remain in an inactive form in the
cytoplasm. However, in response to a variety of stimuli, I𝜅B is
phosphorylated by I𝜅B kinase, resulting in the translocation
of NF-𝜅B into the nucleus to exert its function (Figure 1).The
activation of NF-𝜅B is thought to be part of a stress response
as it is activated by a variety of stimuli that include growth
factors, cytokines, lymphokines, UV, pharmacological agents,
and stress [10, 29]. The activation of NF-𝜅B also occurs in
many malignant cells as a result of genetic mutation rather
than in response to signals from surrounding cells [30]. Most
carcinogens can activate NF-𝜅B, whereas in most tumour
cells, it is kept as a constitutively active protein [31].
NF-𝜅B is considered the “master” gene transcription
factor for promoting inflammation by regulating proin-
flammatory mediators. On the other hand, NF-𝜅B itself is
activated by these same inflammatory cytokines [32, 33].
Studies in mouse models show that NF-𝜅B and TNF-𝛼 are
linked with cancer progression [34, 35]. TNF-𝛼 produced
by neighbouring inflammatory cells can control the acti-
vation of NF-𝜅B and its localisation in cells; this has also
been reported by Greten et al., when they were studying
a mouse colitis-associated cancer model [35]. Their work
does not directly implicate TNF-𝛼, though, but instead found
enhanced production of several proinflammatory cytokines,
including TNF-𝛼, in the tumour microenvironment during
the development of cancer. Both reports demonstrate that
the reduction in NF-𝜅B activation leads to lower incidence
of cancer development [34, 35].
Studies have also shown that other proinflammatory
molecules are indispensable for the initiation, promotion,
and progression of tumour [36–39]. Among these proinflam-
matory mediators, the crucial roles of TNF-𝛼, IL-1, IL-6, IL-
8, COX-2, and iNOS have been mostly highlighted [40, 41].
It has been shown that the expressions of all these mediators
are regulated by transcription factor NF-𝜅B [35, 36, 42]. The
identification of these factors has provided the molecular
basis for the role of inflammation in cancer [23]. They have
also served as the molecular targets in drug design strategies
for both cancer prevention and therapy [23]. We will detail
some of these proinflammatory factors in the latter part of
this review.
NF-𝜅B dimer (e.g., p50 and p65) binds with I𝜅B to remain
an inactive condition in resting cells. For responding to the
stimuli, I𝜅B is degraded by proteasome and the free NF-
𝜅B dimer is translocated from cytoplasm to nucleus. The



















Figure 2: Chemical structure of bufalin and cinobufagin.
activation of NF-𝜅B controls many physiological processes
such as apoptosis, immunity, and proliferation.
4. Current Study of Anti-Inflammatory Agents
in Cancer Prevention and Treatment
Currently, many anticancer agents have been used for the
treatment of inflammatory diseases, such as rheumatoid
arthritis. Meanwhile, the eliminating of inflammation may
provide an efficiency approach for cancer prevention and
therapy [43]. As we mentioned existing epidemiological data
suggest that NSAIDs, the most common of which are aspirin
or ibuprofen, naproxen, and indomethacin, vastly lower the
incidence and motility of breast, colorectal, and lung cancer
[44]. NSAIDs are known as potent anti-inflammatory agents
that act through the inhibition of the COX enzyme and the
subsequent inhibition of prostaglandins which are catalysed
by COX enzymes at the site of inflammation [45]. This type
of drug is usually accompanied by side effects; however, some
studies have suggested that selective COX-2 inhibitors such
as celecoxib may produce superior anti-inflammatory drugs
with substantial safety advantages over existingNSAIDs [46].
Many other cytokine inhibitors are also undergoing
preclinical and clinical trials for the treatment of cancer.
The therapeutic anti-IL-6 antibody, siltuximab (CNTO328),
has been evaluated in Phase II trials of castration-resistant
prostate cancer [47, 48]. Moreover, the anti-TNF-𝛼 antibody
has shown a significant therapeutic effect in inflammatory
and autoimmune diseases which indicates that they may also
have potential in the use for cancer therapy [49–51].
5. The Use of Chansu and Huachansu in
Traditional Chinese Medicine
The dried secretions of the auricular and skin glands of
Bufo bufo gargarizans Cantor or B. melanostictus Schneider
is known as Chansu in TCM [52]. It can be used as a
single agent or more commonly in combination with other
TCMs in a recipe, for example, Liu-shen-wan [43]. Chansu
has been widely used for hundreds of years as an anodyne,
cardiotonic, antimicrobial, and local anaesthetic agent [53].
The anti-infection and anti-inflammatory effect of Chansu
has been recorded in many observational researches in
Chinese publications and medical classics for the treatment
of otitis media, periodontitis, hepatitis, and arthritis [54].
Toad glandular secretions and skin extractions can be
made to different types including oral solution, ointment,
injection, and coating agent. One of the most widely used
commercial preparation is Huachansu (Cinobufacini), which
is a sterilized hot water extract of dried toad skin [55].
Since 1991, Cinobufacini has been officially approved by
the Chinese Food and Drug Administration as a regimen
for treating patients with HBV and several types of cancer
including liver, lung, colon, and pancreatic cancer [56].
An in vivo assay showed that the Cinobufacini injection
inhibits the growing of mouse Lewis lung cancer cells with
the response rate of 45%∼50% and prolongs their life [57].
Clinical trials of Cinobufacini injection have been conducted
since the 1970s within China. The results have demonstrated
the anticancer effect of Cinobufacini injection in advanced
hepatocellular carcinoma and lung cancer patients with a
total response rate of 10% and 16%, respectively [58]. A Phase
I clinical trial conducted by Meng et al. further examined
the tolerable toxicity in patients. The result showed that
Cinobufacini injection can be tolerated up to 8 times higher
than normal administrated does. Up to 40% lung and liver
cancer patients had tumours stabilised in this trail [59].
Additionally, Cinobufacini injection promoted the efficacy
of the conventional therapies while lowering their toxicity
when it was used in combination with chemotherapy or
radiotherapy [60, 61]. To fully reveal the anticancer property
as well as the underlined mechanism of this drug, more
preclinical study and clinical trials are needed.
6. Compounds in Chansu and Huachansu
Several classes of compounds including bufadienolides,
steroids, indole alkaloids, peptides, organic acids, and others
have been analysed and isolated by variousmethods from the
auricular and skin glands of different species of toads as listed
in Table 1 [62, 63].
Bufadienolides such as bufalin and cinobufagin (Figure 2)
are recognised as the major bioactive components in Chansu
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and Huachansu. This group of chemicals has been known as
cardiac glycosides (Table 1) [56, 64].
7. The Anticancer Studies of
Cardiac Glycosides
Therapeutic uses of cardiac glycosides primarily are involved
in the treatment of cardiac failure. However, recent studies
showed that this type of chemical structure also exerts effects
in cancer therapy [56, 64]. Ye et al. showed bufalin and
other cardiac glycoside inhibitors of the sodium pump block
the activation of the transcription factors IRF3 and NF-𝜅B
by inhibiting the induction of interferon-𝛽. They have also
showed that bufalin blocks tumour necrosis factor (TNF) sig-
nalling, at least in part bymediating the nuclear translocation
of NF-𝜅B. [65]. Yang et al. showed that cardiac glycosides
block the activation of the TNF-𝛼/NF-𝜅B signalling pathway
in Hela cells [66]. Another study showed that cardiac glyco-
sides prevent lipopolysaccharide (LPS)-induced activation of
proinflammatory cytokines including TNF-𝛼, IL-1 and IL-6
in whole blood at least partly through an NF-𝜅B-dependent
mechanism and also can inhibit IL-8 in various cells types
[67]. Moreover, a mouse model study also showed that this
group of cardiac glycoside structurally related compounds
can suppress the expression ofNF-𝜅B and I𝜅B aswell as COX-
2 in skin cancer [68]. These findings indicate that cardiac
glycosides including bufalin have a potent role in treating
inflammatory and autoimmune diseases.
8. Mechanisms of Action of
Toad Glandular Secretions and Skin
Extractions as Anti-Inflammatory and
Anticancer Agents
8.1. Targeting Cancer-Related Inflammation. The molecular
mechanisms of toad glandular secretions and skin extractions
have recently been the focus of several studies and the
anti-inflammatory property has been looked at in several
inflammatory and cancer models (Table 2). However, current
studies are limited and further investigations are required
to fill the gaps. Here, we review some current research
progresses.
Dong et al. investigated the effect of the single compound
cinobufagin on liver cancer cell line HepG2 and found
that cinobufagin significantly suppressed NF-𝜅B p65 protein
expression [74]. Jiang et al. found that bufalin at the con-
centration of 2.5–10𝜇M reduced expression level of COX-2
protein in A549 cells. In addition, they also found that bufalin
suppressed the phosphorylation and expression of NF-𝜅B
[75]. Chen et al. demonstrated that bufalin inhibits migration
and invasion in human hepatocellular carcinoma SK-Hep1
cells at least partly by the inhibition of NF-𝜅B signalling
pathway [76]. In another study, the nitric oxide (NO) regu-
latory effect of Chansu and bufalin was studied by Bhuiyan
et al. on BeWo cells. Their study indicated that Chansu at
the concentration of 5–10𝜇g/mL significantly up-regulated
NO production to 110% of basal control value, while at a
higher concentration of 40–80𝜇g/mL, Chansu decreasedNO
Table 1: Chemical properties of Chansu and Huachansu.
Objective Method Compounds Reference

























































iNOS, COX-2, NO, PGE2,
TNF-𝛼, IL-1𝛽, IL-12, I𝜅B-𝛼 [78]
COX-2, PGE2 [79]
Huachansu NF-𝜅B, COX-2, IL-6, IL-8 [80]
Liu-shen-wan TNF-𝛼, IL-1 [81]
production. A similar result was also observed with bufalin
in this study [77]. INOS is one of three identified enzymes of
nitric oxide synthase family, which catalyse the production
of nitric oxide (NO) from L-arginine [82]. iNOS-derived
NO is a vital cellular signalling molecule which is associ-
ated with many physiological and pathological processes,
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including inflammation and carcinogenesis [83]. Increased
expression of iNOShas been observed in tumours aswell as in
chronic inflammatory diseases [84]. Chronic inflammatory
conditions induce overexpression of iNOS which generate
sustainable NO, and its reactive intermediates are mutagenic,
which result in DNA damage or absence of DNA repair.
Recent studies indicate NO as a key signalling molecule
that regulates processes of tumourigenesis. The development
of selective inhibitors of iNOS and NO-releasing agents is
underway and this may lead to important strategies for
chemoprevention of cancer [85].
In another study, Kim et al. found that Chansu sig-
nificantly inhibits iNOS and COX-2 mRNA and protein
expression as well as the production of NO and Prostaglandin
E2 (PGE2) in LPS-stimulated BV2 microglial cells. Their
study also showed that Chansu inhibited the production
of TNF-𝛼, IL-1𝛽, and IL-12 and the degradation of I𝜅B-𝛼,
which was considered to be inhibitor of NF-𝜅B [78]. Ko et al.
indicated that Chansu inhibited the level of COX-2 mRNA
and protein expression and also the PGE2 synthesis without
significant influence on the level of COX-1 in human bladder
carcinoma T24 cells [79].
In an in vitro study on tumour cells, Wang et al. inves-
tigated the effects of Huachansu on NF-𝜅B, COX-2 and
the proinflammatory cytokines IL-6 and IL-8 induced by
TNF-𝛼 in the A549 cell line. They found that Huachansu
inhibited NF-𝜅B and COX-2 activation induced by TNF-
𝛼 and decreased the expression levels of proinflammatory
cytokines IL-6 and IL-8 [80].
Chansu can be also combined with other TCMs in a
recipe, such as Liu-shen-wan (LSW), for the treatment of
many other health conditions. The ingredients of LSW are
Zhenzhufeng, Niuhuang, Shexiang, Xionghuang, Bingpian,
and Chansu [86]. It has been used for various purulent
infections clinically because of immune-enhancing, antimi-
crobial, anti-inflammatory, and cardiotonic activities. Ma
et al. showed that LSW significantly reduced the levels of
circulating TNF-𝛼 while there was a slight decrease in the
levels of IL-1 in mousemacrophage, which suggests that LSW
enhances the beneficial host defense function at the primary
site of infection andweakens harmful inflammatory response
at other sites [81].
8.2. Anti-Infection. The antimicrobial activity of telocinob-
ufagin and marinobufagin was performed by liquid growth
inhibition against two types of bacteria. The result has
shown that the minimum inhibitory concentrations of telo-
cinobufagin and marinobufagin were 64.0 and 16.0𝜇g/mL,
respectively, for E. coli while both 128 𝜇g/mL for S. aureus
[87]. Cui et al. examined the antihepatitis B virus (HBV)
activities of Cinobufacini and its active component bufalin
and cinobufagin in the human HBV-transfected cell line
HepG2.2.15. Results suggested that Cinobufacini had more
potent activity against HBV antigen secretion than its com-
ponents bufalin and cinobufagin and this inhibitory role was
attributed to the specific inhibition ofHBVmRNAexpression
[88].
8.3. Immunomodulatory Effect. Numerous diseases including
cancer are often associated with depression of the immune
system [89]. Some researchers have also shown that Chansu
and Huachansu, as well as their active components, are
immunomodulators which enhance the function of immune
system.
In an in vitro assay, cinobufagin was shown to have
markedly effects on the cell proliferation splenocytes and
peritoneal macrophages (PMF) and enhanced the phagocytic
activation of PMF. Additionally, the ratios of CD4+ CD8+
double-positive T-cell and S-phase cells of splenic lympho-
cytes are also increased by the treatment of cinobufagin. Fur-
thermore, the levels of Th1 cytokines, including interferon-𝛾
andTNF-𝛼, were significantly enhanced, whereas the levels of
the Th2 cytokine IL-4 and IL-10 were dramatically reduced.
As a result, the percentage of Th1/Th2 is also up-regulated
[90]. In a study by Cao et al., telocinobufagin was found
to significantly stimulate splenocyte proliferation and to
enhance natural killer cell and PMF activation in BALB/c
mice. Telocinobufagin significantly increased the percentage
of CD4+ and CD8+ T cell populations. Moreover, Cao et al.
found that the levels of Th1 cytokines including IL-2, IL-12,
IFN-𝛾 and TNF-𝛼were sharply elevated after telocinobufagin
treatment, while the level of the Th2 cytokine IL-4 was
significantly lowered, leading to an increased ratio ofTh1/Th2
[91]. Liu et al. found that Cinobufacini injection at the
concentration of 0.0625–0.5𝜇g/mL increased the expression
of IL-2 in splenic lymphocytes of mice with enhanced T
lymphocyte dependent immune responses [92].These results
suggest that the active compounds in Chansu andHuachansu
have potential immunomodulatory properties. More work is
needed for development of novel immunotherapeutic agents
from toad glandular secretions and skin extractions for
treating cancer.
8.4. Induction of Tumour Cells into Apoptosis. In recent
years, there are a growing number of studies indicating
that apoptosis is a key process in cancer development and
progression. Apoptosis is a specific process that leads to
programmed cell death, which is essential in the homeostasis
of normal tissues of the body and the dysregulation of this
process may cause many diseases such as cancer.
The expression of tumour cell apoptosis-related genes
plays an important regulatory role in the tumour devel-
opment process. Some gene deletion, mutation, or overex-
pression within this process may lead to uncontrolled cell
proliferation or apoptosis blockage. Therefore, regulation
of apoptosis-related genes or their corresponding products
improves the sensitivity of tumour cells to drugs and induces
cells apoptosis which is the key in cancer treatment.
A number of studies have revealed the effect of Chansu,
Huachansu, and their single compound on inducing lung,
colon, breast, and prostate cancer and a wide range of
tumour cell lines into apoptosis [93]. Yun et al. have indicated
that Chansu induces the apoptosis of A549 cells through a
signalling cascade of death receptor-mediated extrinsic and
mitochondria-mediated intrinsic caspase pathways. In their
study, the treatment with Chansu down-regulated the anti-
apoptotic Bcl-2 expression andup-regulated proapoptotic Fas
ligand and death receptor 4 while reduced the mitochondrial
membrane potential. Additionally, the proteolytic activation
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of caspases and a concomitant degradation of poly- (ADP-
ribose-) polymerase and 𝛽-catenin protein were found after
treatment with Chansu. Cleavage of Bid and a downregu-
lation of the inhibitor of apoptosis family of proteins were
also observed in this study [94]. Another study from Wang
et al. concluded that the apoptosis of A549 cells can be
induced by Cinobufacini through the decreased expression
of survivin and the increased caspase-3 activity [95]. In a
study of bufadienolides, the antiproliferative and apoptotic
mechanisms of prostate cancer cells LNCaP, DU145, and
PC3 treated with bufalin and cinobufagin were investigated.
After treatment with bufalin and cinobufagin, the caspase-
3 activity, protein expression of caspase-3, -8, and -9, and
other apoptoticmodulators includingmitochondrial Bax and
cytosolic cytochrome 𝑐 were elevated. The increased expres-
sion of p53 was only observed in LNCaP cells. Additionally,
the reduction of p53 by antisense TP53 restored the cell
viability suppressed by bufalin and cinobufagin. Their study
also indicated that the increased expression of Fas was more
significant in DU145 and PC3 cells with mutant p53 than
in LNCaP cells. The transfection of Fas small interfering
RNA restored cell viability in the bufadienolide-treated cells
[96, 97].
8.5. Efficacy and Safety. The side effects caused by Chansu
and Huachansu are thought to be mainly contributed by
its cardiac glycoside property [98]. However, a recent study
showed that it is possible to alleviate such toxicity by using
long circulating liposomes which could enhance the ther-
apeutic effects of bufadienolides and reduce their toxicity.
Hu et al. found that the bufadienolide liposomes had an
LD50 that was 3.5 time higher than the LD50 of bufa-
dienolide solution without severe toxicity [99]. Another
study also showed that bufadienolide-loaded nanostructured
lipid carriers were safe when given by intravenous injection
with reduced toxicity [100]. Ma et al. showed that Bezoar
Bovis, which is a TCM usually in combination with Chansu,
can protect against Chansu-induced acute toxicity in mice.
Additionally, their anti-inflammatory study also showed that
Bezoar Bovis did not reduce the anti-inflammatory activity
of Chansu and Huachansu on concanavalin-A-stimulated
proliferation of human peripheral blood mononuclear cells
[101].
9. Conclusion
Current conventional cancer therapies are mostly surgery,
chemotherapy, and radiotherapy. However, problems such
as metastasis and tumour resistance to chemotherapy and
radiotherapy have seriously limited the therapeutic effects of
existing clinical treatments [102]. Studies have shown that
toad glandular secretions and skin extractions contain many
chemical compounds which possess both anti-inflammatory
and anticancer properties and can be used as complemen-
tary and combinational agents to conventional therapies on
cancer treatment. Thus, it is invaluable to study the anti-
inflammatory activity of their bioactive constitutes by target-
ing inflammatory mediators in cancer not only to establish
anti-inflammatory mechanisms, but also to develop a new
class of anti-inflammatory agents which may be useful in
the prevention and treatment of cancer. Present studies have
shown that toadmedicines decrease inflammation and cancer
through a variety of mechanisms, including inhibition of NF-
𝜅B and its signalling molecules and pathways. Preclinical
studies also suggested that many cardiac glycosides derived
from Chansu and Huachansu have potent activity against
cancer cells, which prevent carcinogenesis or metastasis of
existing tumours. Therefore, toad glandular secretion and
skin extraction have a real potential as resources for the devel-
opment of therapeutical agents for preventing or treating
human cancers by inducing apoptosis, sensitizing cancer cells
to conventional cancer therapies, or protecting host cells from
any side effects.
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